Published in FASEB BioAdvances · View the paper (DOI)
A recent study suggests that a unique human genetic mutation may contribute to the high risk of advanced cancers, with approximately 30% of people still producing dysfunctional Siglec-12 proteins. These individuals are at twice the risk of developing advanced cancer compared to those who cannot produce the protein.
Coverage from 2 institutions